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ABSTRACT
Objective: To evaluate the use of percutaneous tibial nerve stimulation (PTNS) in an elderly
population, as PTNS is a third-line treatment in the management of overactive bladder (OAB) and
aﬀects 10–26% of adult males and 8–42% of adult females, increasing in prevalence with age.
Patients and methods: We performed a chart review of patients aged ≥ 65 years undergoing
PTNS at a single institution over 6 years. We examined clinicopathological variables poten-
tially associated with the outcomes of interest.
Results: In total, 52 patients aged ≥ 65 years underwent an induction course of PTNS between
2011 and 2017, comprising 23men and 29 women. Themean age of the patients was 75.75 years
and the mean body mass index (BMI) was 26.33 kg/m2. In all, 36 patients used anticholinergic
treatments prior to PTNS, ﬁve used a β3-adrenoceptor agonist, and three had Botox injections.
After PTNS, 37 patients reported improvement of their symptoms, with 21 using combined
therapy during PTNS. Only seven patients used an anticholinergic after PTNS, six used a β3-
adrenoceptor agonist, ﬁve had Botox injections, and two had sacral neuromodulation. When
looking at variables such as age, gender, race, BMI, and comorbidities, we found that an obese
BMI was the only statistically signiﬁcant variable predicting failure of response. A sub-analysis of
only women did not demonstrate any predictors of failure.
Conclusion: Our subjective response rate of 70% was within the success rates reported in
literature. In all, 39% of patients used a concomitant treatment during PTNS and 13.2%
required alternative treatment after PTNS.
Abbreviations: BMI: body mass index; OAB: overactive bladder; PTNS: percutaneous tibial
nerve stimulation; UI: urinary incontinence
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Introduction
Overactive bladder (OAB) syndrome is deﬁned by the
ICS as ‘urinary urgency, usually accompanied by fre-
quency and nocturia, with or without urgency urinary
incontinence, in the absence of urinary tract infection
(UTI) or other obvious pathology’ [1]. It is a condition
that has been estimated to aﬀect up to 34 million
Americans, with estimates of 546 million people
aﬀected worldwide by 2018, and can have signiﬁcant
detrimental eﬀects on quality of life [2]. It is also
known that the prevalence of OAB increases with
age [3,4]. The prevalence of urinary incontinence (UI)
in women has been shown to increase through adult-
hood, with up to 39% of women aged > 60 years with
daily urge UI [4]. Men have a lower prevalence, with
up to 11% for daily urge UI episodes when aged
> 65 years [4].
Recommended ﬁrst-line treatment for OAB includes
behavioural therapy, which should be oﬀered to all
patients. Behavioural modiﬁcations may then be com-
bined with pharmacological therapy in an attempt to
minimise symptoms and improve quality of life; however,
there is a high discontinuation rate of anticholinergics,
with reports of only 18% of patients compliant after
6months [5,6]. Third-line treatment options include intra-
vesical onabotulinumtoxinA injections, sacral neuromo-
dulation, or percutaneous tibial nerve stimulation (PTNS)
[5]. PTNS was approved for treatment of OAB in 2000. It
acts by stimulating the aﬀerent ﬁbres of the tibial nerve
(L4–S3). It is a less invasive form of neuromodulation
therapy than sacral neuromodulation; however, it
requires a motivated patient to return weekly for
12 weeks [6].
The elderly population is unique, with increased med-
ical comorbidities and the possibility for cognitive and
functional deﬁcits. To date, there is a paucity of studies
looking at this speciﬁc patient population regarding the
PTNS treatment modality. Our primary aim in the present
studywas to describe our clinical experiencewith PTNS in
an elderly population and report treatment response,
concomitant therapies, and alternative treatments
needed after therapy. Our secondary aim was to look
speciﬁcally at elderly women, to determine if there is
a diﬀerence in response based on gender.
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Patients and methods
This is a retrospective chart review of patients aged
≥ 65 years undergoing a 12-session induction course
of PTNS at a single institution over a 6-year period
between 2011 and 2017. The study was approved by
the Institutional Review Board of the University of
California, Irvine (HS#2016–2976). Using the Current
Procedural Terminology (CPT) codes for PTNS (64,566),
a procedure total of 499 charts were identiﬁed and
reviewed. Only patients undergoing PTNS for idio-
pathic OAB, and who had completed the 12-week
session treatment were included. We excluded neuro-
genic bladder, urinary retention, or patients with
chronic pelvic pain syndrome. A total of 52 patients
were included in the analysis who met the inclusion
criteria. Demographic data included patient’s age, sex,
body mass index (BMI), race, and medical comorbid-
ities. Assessment of the patients’ OAB symptoms were
obtained at baseline and after the induction course of
PTNS using the validated eight-item OAB question-
naire (OAB-V8), 3-day voiding diary, as well as the
Patient Global Impression of Satisfaction (PGI-S) after
treatment. In addition, we recorded if patients
required concomitant therapy during PTNS, as well
as if alternative therapy, such as intravesical
onabotulinumtoxinA injections, anticholinergic or β-
agonist medications, or sacral neuromodulation was
needed following PTNS treatment.
Brieﬂy, the tibial nerve is located just anterior to the
Achilles tendon cephalad to the medial malleolus [7].
PTNS is performed by placing a 34-G needle 3–5 cm
cephalad to the medial malleolus and posterior to the
tibia, at 60 ° (Figure 1) [8,9]. A grounding pad is placed
on the bottom of the foot, after which a low-voltage
stimulator is attached to the needle. Correct needle
placement is conﬁrmed by observing dorsiﬂexion of
the big toe or a fanning of the toes, as well as patient-
reported sensation on the bottom of the foot.
Stimulation is typically performed at 0.5–9.0 mA ampli-
tude at a ﬁxed frequency of 20 Hz and a set pulse width
of 200 µs, based on patient sensation, motor response,
and comfort [6,9]. The induction treatment course con-
sists of 12 consecutive weekly sessions, for 30 min per-
session. If patients report a good response, measured as
a > 50% improvement in symptoms, they may continue
with once monthly maintenance treatment.
Statistical analysis was performed using an unpaired
t-test for continuous variables, summarised with mean,
SDs, and SEMs. Categorical variables, such as medical
comorbidities, gender, and race, were analysed using
chi-squared analysis. A logistic regression, multivariate
analysis was performed to identify predictive factors for
patients who would beneﬁt most from PTNS treatment.
P values generated from chi-squared tests for categori-
cal variables and t-tests for continuous variables were
reported. A P < 0.05 was considered to indicate statis-
tical signiﬁcance.
Results
A total of 499 charts were reviewed. After accounting for
multiple visits per induction of treatment course, 52
patients were eligible for inclusion. In all, 23 of the
patients were men (44.3%) and 29 were women
(55.8%). The mean (range) age of patients was 75.75
(65–93) years and BMI was 26.33 (17.4–43.9) kg/m2. In
all, 34 patients self-identiﬁed as White, and 18 identiﬁed
as non-White. There were 18 patients (34%) with one to
two medical comorbidities, 22 (43.4%) with three to four
medical comorbidities, and 12 (22.6%) hadmore than ﬁve
comorbidities. Anticholinergic treatments were used by
36 patients (69%) prior to PTNS, ﬁve used a β3-
adrenoceptor agonist, and three had intravesical
onabotulinumtoxinA injections. Overall, 21 patients
Figure 1. Anatomy of the tibial nerve in relation to the medial malleolus.
ARAB JOURNAL OF UROLOGY 11
(39%) used combined therapy during PTNS. After PTNS,
37 patients (70%) reported improvement of their symp-
toms. Only seven patients used an anticholinergic after
PTNS, six patients used a β3-adrenoceptor agonist, ﬁve
had intravesical onabotulinumtoxinA injections, and two
underwent sacral neuromodulation.
Of the patients who reported improvement with
PTNS, the average BMI was 25.08 kg/m2. The average
BMI of patients without improvement with PTNS was
29.23 kg/m2. When looking at variables such as age,
gender, race, BMI, and comorbidities, we found an
obese BMI (≥ 30 kg/m2) to be the only statistically
signiﬁcant variable predicting failure of response
(P = 0.002). We then performed a logistic regression,
multivariate analysis and found that none of these fac-
tors were predictive of the improvement of treatment
after PTNS. Of elderly patients who received intravesical
onabotulinumtoxinA injections with continued symp-
toms, all reported symptom improvement following
PTNS.
We then performed a sub-analysis on women in the
cohort. With women aged > 65 years, the average age
was 74.2 years, with an average BMI of 28.2 kg/m2. In
our group of elderly women, 13 had one to two med-
ical comorbidities, 10 had three to four medical comor-
bidities, and six had more than ﬁve comorbidities. In
all, 20 women (69%) used anticholinergic treatments
prior to PTNS, one used a β3-adrenoceptor agonist, and
one had intravesical onabotulinumtoxinA injections.
There were 11 women (38%) who used combined
therapy during PTNS. After PTNS, 19 women (66%)
reported improvement of their symptoms. Only two
women (7%) used an anticholinergic after PTNS, six
used a β3-adrenoceptor agonist, four had intravesical
onabotulinumtoxinA injections, and none of the
women underwent sacral neuromodulation. These
values are similar to the overall cohort with both gen-
ders combined. However, when looking at women
alone, BMI was not a statistically signiﬁcant variable
predicting failure of response (P = 0.883).
Discussion
In our present population of elderly patients under-
going PTNS for OAB, we found a subjective success
rate of 70% overall and 66% for women only, which is
well within the established success rates reported in the
literature of 37–82% [6]. Our present study demon-
strated a signiﬁcant decrease in the use of anticholiner-
gics following PTNS, as 36 (67.9%) patients used an
anticholinergic prior to therapy and only seven (13.2%)
used an anticholinergic after therapy. An obese BMI was
the only variable predictive of failure in our present
cohort, which was the same in our control group. This
was not predictive of failure in women alone. An inter-
esting ﬁnding was that all of the patients who had failed
intravesical onabotulinumtoxinA injections had
a favourable response after completing the PTNS
course. In elderly women only, the results were similar,
demonstrating good success in both men and women.
Our present study compares to a meta-analysis of four
non-comparative studies with a pooled subjective suc-
cess rate of 60.6% [6]. It also has similar ﬁndings to those
of George et al. [10], who reported that an obese BMI
trended towards being a predictive factor for patients
undergoing sacral neuromodulation beneﬁting from sup-
plemental treatment with an anticholinergic. They
hypothesise that this may be due to increased diﬃculty
when placing the electrode in an ideal location [10]. In
contrast, Peters et al. [11] found that those undergoing re-
operation for sacral neuromodulation had a statistically
lower BMI. We hypothesise that a higher BMI may predict
a lower success rate in our patients undergoing PTNS due
to the increased amount of tissue that the voltage con-
ducts through. Amundsen et al. [12] found that patients
with three or more medical comorbidities had a lower
cure rate after sacral neuromodulation; however, our pre-
sent study did not show an association between number
of comorbidities and response, in either the combined
gender cohort or women alone.
The present investigation is important as the popula-
tion continues to age. According to the USA Census
Bureau, 2012 National Projections predict signiﬁcant
population growth between 2012 and 2050, with
83.7 million people becoming aged ≥ 65 years [13]. This
value is almost double the elderly population of
43.1 million in 2012 [13]. This will have a signiﬁcant
impact on healthcare and predicted need for adjust-
ments to deliver optimal patient-centric care.
Anticholinergics have been a mainstay for the treatment
of OAB [14,15]. However, compliance is low due to poten-
tial side-eﬀects [15,16]. In 1991, the American Geriatrics
Society ﬁrst published the Beers Criteria for Potentially
Inappropriate Medication Use in Older Adults, with the
most recent update published in 2015 [17].
Anticholinergics are included in this evidence-based list
of medications that should be avoided in older adults, as
this class of drugs also has an increased risk of cognitive
decline, with the strength of the recommendation rated
as ‘strong’ [17]. Clinicians should also avoid prescribing
this class of medication in older adults to avoid the risk of
polypharmacy [18]. Our present study demonstrates that
PTNS is a viable, minimally invasive option for the treat-
ment of OAB in an elderly population, to minimise the
addition of another medication in a population who may
be prone to increased adverse eﬀects due to
medications.
We recognise some limitations to our present study.
This is a retrospective descriptive study and has a small
sample size, which perhapsweakens our study’s statistical
power and results. The present study could be strength-
ened by using objective measures of success to PTNS,
such as changes in bladder diary or urodynamic para-
meters. The use of additional validated questionnaires
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would have strengthened the analysis as well. Finally,
datawere collected retrospectively and thuswere subject
to the ﬂaws inherent in a retrospective design, such as
recall or misclassiﬁcation bias, as well as subject to other
confounding variables. However, all laboratory and clin-
ical data for the patients were recorded in the electronic
ambulatory medical charts. The collection of data by
researchers was strict and thorough to minimise the bias
and ﬂaws of retrospective studies. PTNS therapy requires
amotivated patientwith the time forweekly follow-up for
12weeks, aswell as a reliablemeans of transportation.We
recognise this is not always feasible for an elderly
population.
Conclusion
In conclusion, the present study highlights the eﬀective-
ness and viability of PTNS as a treatment alternative for
OAB in the elderly population. Special consideration
should be taken for this unique patient population. We
suggest that current treatment algorithms for OAB be
modiﬁed for the elderly, as PTNS may be an
appropriate second-line treatment option, over pharma-
cotherapy. Although, we believe that treatment selection
should be a patient-centric decision, it is not necessarily
to be in a step-wise manner. Beside that, if the patient
switches to another line it is not necessary to stop the
treatment of the other line for example; we still encour-
aged patients to continue the behavioural modiﬁcation
and do PTNS and/or other second- or third-line OAB
treatments. Our experience with PTNS in this population
demonstrates a large decrease in anticholinergic use
following PTNS, in conjunction with high subjective suc-
cess rates. In addition, PTNS should be kept as an option
for those who fail intravesical onabotulinumtoxinA
injections.
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